Estée Lauder
No proof required
Up to $5,000
Claims opening soon
J
Johnson & Johnson / Janssen Biotech
A $25 million settlement has been reached to resolve claims that Johnson & Johnson and Janssen Biotech suppressed generic Remicade competitors.
ClosedUnited States-wideClaim status: Closed on November 30, 2022Payout: VariesNo longer claimable
About this settlement
Allegations of suppressing generic Remicade (infliximab) competitors.
This settlement resolves claims that Johnson & Johnson and Janssen Biotech suppressed generic competitors for their drug Remicade. The settlement benefits individuals and entities who indirectly purchased, paid for, or were reimbursed for Remicade between April 5, 2016, and Feb. 28, 2022. Proof of purchase is required.
Who qualifies
- Individuals and entities who indirectly purchased, paid for, or were reimbursed for Remicade.
- Purchases made between April 5, 2016, and Feb. 28, 2022.
Varies
Claim status: Closed on November 30, 2022
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
643 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon
Apple
No proof required
Up to $100
Claims opening soon